Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 886-895

  Marijnissen, Renoud J ^a   Roeleveld, Debbie M ^a   Young, Deborah ^b   Nickerson Nutter, Cheryl ^b   Abdollahi Roodsaz, Shahla ^a   Garcia De Aquino, Sabrina ^a,d   Van De Loo, Fons A J ^a   Van Spriel, Annemiek B ^a   Boots, Annemieke M H ^c,e   Van Den Berg, Wim B ^a   Koenders, Marije I ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PFIZER INC   (United States)

^c NV ORGANON   (Netherlands)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; EXPERIMENTAL ARTHRITIS; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; JOINT DESTRUCTION; JOINT SWELLING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STREPTOCOCCAL CELL WALL ARTHRITIS; SYNOVIUM; TH1 CELL; TH17 CELL; UPREGULATION; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, INFECTIOUS; JOINTS; MICE; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION; STREPTOCOCCAL INFECTIONS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SYNOVIAL MEMBRANE; TH1 CELLS; TH17 CELLS; TOLL-LIKE RECEPTOR 2; UP-REGULATION;

EID: 84898604331     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38312     Document Type: Article

References (28)

1. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL,. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 2011; 13: R126.
2. Koenders MI, Marijnissen RJ, Devesa I, Lubberts E, Joosten LA, Roth J, et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011; 63: 2329-39.
3. Koenders MI, Marijnissen RJ, Joosten LA, Abdollahi-Roodsaz S, Di Padova FE, van de Loo FA, et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum 2012; 64: 1762-70.
4. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408: 57-63.
5. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298: 1630-4.
6. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005; 175: 7867-79.
7. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007; 179: 5886-96.
8. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C,. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008; 29: 127-37.
9. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448: 480-3.
10. H17 cells. Nature 2007; 448: 484-7.
11. H17 cells. Nature 2008; 454: 350-2.
12. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ,. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2008; 105: 14028-33.
13. Kwok SK, Cho ML, Park MK, Oh HJ, Park JS, Her YM, et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum 2012; 64: 740-51.
14. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50: 1468-76.
15. Li J, Shen W, Kong K, Liu Z,. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006; 64: 515-22.
16. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007; 56: 1152-63.
17. Van den Broek MF, van den Berg WB, van de Putte LBA, Severijnen AJ,. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol 1988; 133: 139-49.
18. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis [review]. Nat Rev Immunol 2007; 7: 429-42.
19. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
20. Koenders MI, Joosten LA, van den Berg WB,. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis [review]. Ann Rheum Dis 2006; 65 Suppl 3: iii29-33.
21. Iwakura Y, Ishigame H, Saijo S, Nakae S,. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-62.
22. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005; 167: 141-9.
23. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP,. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54: 158-68.
24. - T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J Immunol 2009; 182: 4649-56.
25. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003; 171: 6145-53.
26. Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen MM, van den Bersselaar LA, Oppers-Walgreen B, et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1β and interleukin-17. Arthritis Rheum 2008; 58: 98-108.
27. Liew FY, Xu D, Brint EK, O'Neill LA,. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446-58.
28. Strengell M, Lehtonen A, Matikainen S, Julkunen I,. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. J Leukoc Biol 2006; 79: 1279-85.